The Technical AnalystExchange: WSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Celon Pharma S.A. Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.20% PLN16.84
America/New_York / 17 mai 2024 @ 11:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 859.79 mill |
| EPS: | -0.550 |
| P/E: | -30.62 |
| Earnings Date: | May 22, 2024 |
| SharesOutstanding: | 51.06 mill |
| Avg Daily Volume: | 0.0290 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -30.62 | sector: PE 21.29 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -30.62 | industry: PE -48.35 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
PLN 16.51 - 17.18 ( +/- 1.99%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | PLN16.84 (1.20% ) |
| Volume | 0.0653 mill |
| Avg. Vol. | 0.0290 mill |
| % of Avg. Vol | 225.21 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CLN.WA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CLN.WA
Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary of Glatton Sp. z o.o.